ACIP Prefers mRNA COVID-19 Vaccines, But Worries Message May Not Resonate
Executive Summary
Advisory committee says that clinical guidelines and other communications must include strong belief mRNA vaccines should be given over Janssen’s adenovirus vaccine.
You may also be interested in...
Is A Class-Wide Myocarditis Warning Coming For COVID-19 Vaccines?
Now that multiple vaccines using different platforms seem to be associated with heart inflammation, the FDA and others want more data on whether a common characteristic of the virus or vaccine manufacturing is related.
COVID-19 Vaccines: With Narrowed Authorization For Janssen, US FDA Catches Up To CDC
Citing risk of thrombosis with thrombocytopenia syndrome, FDA restricts adenovirus-based vaccine to adults for whom other vaccines are not accessible or clinically appropriate, or who would not otherwise get a vaccine; action comes almost five months after CDC decided to preferentially favor the mRNA vaccines from Pfizer/BioNTech and Moderna.
Janssen COVID-19 Vaccine Adds Another Thrombotic Warning
US FDA adds a warning about immune thrombocytopenia, joining the risk of Thrombosis with Thrombocytopenia Syndrome.